10x Genomics CEO sells 18,545 shares for taxes

10x Genomics, Inc. (TXG) reported an insider transaction by Chief Executive Officer and director Serge Saxonov.

Rhea-AI Filing Summary

10x Genomics, Inc. (TXG) reported an insider transaction by Chief Executive Officer and director Serge Saxonov. On 2026-08-24, he sold 18,545 shares of Class A Common Stock at a weighted average price of $63.0237 per share in open-market trades, solely to cover tax withholding obligations arising from the vesting of restricted stock units. After this sale, he directly held 1,085,835 shares of Class A Common Stock and also had indirect holdings through three trusts for which he serves as trustee.

Insider Trade Summary

Net Seller: 18,545 shares

Net Sell 4 txns

Insider Saxonov Serge

Role Chief Executive Officer

Sold 18,545 shs ($1.17M)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1, F2	18,545	$63.0237	$1.17M
holding	Class A Common Stock F3	--	--	--
holding	Class A Common Stock F4	--	--	--
holding	Class A Common Stock F5	--	--	--

Holdings After Transaction: Class A Common Stock — 1,085,835 shares (Direct); Class A Common Stock — 284,921 shares (Indirect, See footnote)

Footnotes (5)

1. F1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
2. F2. This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. F3. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
4. F4. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
5. F5. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

Key Figures

Shares sold: 18,545 shares of Class A Common Stock Weighted average sale price: $63.0237 per share Post-transaction direct holdings: 1,085,835 shares of Class A Common Stock +2 more

5 metrics

Shares sold 18,545 shares of Class A Common Stock Sale by CEO Serge Saxonov on 2026-08-24

Weighted average sale price $63.0237 per share Tax-withholding sale of 18,545 shares on 2026-08-24

Post-transaction direct holdings 1,085,835 shares of Class A Common Stock Direct ownership by Serge Saxonov after the sale

Sale price range $63.0088 to $63.78 per share Multiple trades executed on 2026-08-24

Net buy/sell shares −18,545 shares Net result of reported non-derivative transactions in this Form 4

Key Terms

restricted stock units, weighted average sale price, indirect ownership, tax withholding obligations

4 terms

restricted stock units financial

"tax withholding obligations in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

indirect ownership financial

"The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee."

tax withholding obligations financial

"shares were sold to cover tax withholding obligations in connection with the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TXG CEO Serge Saxonov report in this Form 4 filing?

He reported a sale of 18,545 TXG Class A shares on 2026-08-24 at a weighted average price of $63.0237 per share, conducted in open-market trades to cover tax withholding obligations from vesting restricted stock units.

How many TXG shares does Serge Saxonov hold directly after this transaction?

After the reported sale, Serge Saxonov directly holds 1,085,835 shares of 10x Genomics, Inc. Class A Common Stock, according to the Form 4 disclosure.

Why did the TXG CEO sell 18,545 shares on 2026-08-24?

The filing states the 18,545 shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units, rather than as a discretionary sale of investment holdings.

What price range were the TXG shares sold at in this Form 4?

The reported transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78 per share. The Form 4 reports a weighted average sale price of $63.0237 per share.

Does Serge Saxonov have indirect holdings of TXG shares?

Yes. The Form 4 notes additional TXG shares are held by the Andromeda Trust, the Y/S Descendants' Trust, and the Y/S Pot Trust, with Serge Saxonov serving as trustee for each, reported as indirect ownership.

Was this TXG insider sale under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not checked, and the footnotes do not describe a trading plan, so the sale is not identified as made pursuant to a Rule 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/26/2026 - 04:46 PM EDT Accepted by SEC EDGAR 08/26/2026 - 04:46 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saxonov Serge

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CALIFORNIA 94588

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/24/2026		S(1)		18,545	D	$63.0237(2)	1,085,835	D
Class A Common Stock								27	I	See footnote(3)
Class A Common Stock								213,250	I	See footnote(4)
Class A Common Stock								71,644	I	See footnote(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

2. This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

4. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

5. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

	/s/ Randy Wu, as Attorney-in-Fact for Serge Saxonov	08/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)